[go: up one dir, main page]

MA32656B1 - Nouveaux composes chimiques - Google Patents

Nouveaux composes chimiques

Info

Publication number
MA32656B1
MA32656B1 MA33729A MA33729A MA32656B1 MA 32656 B1 MA32656 B1 MA 32656B1 MA 33729 A MA33729 A MA 33729A MA 33729 A MA33729 A MA 33729A MA 32656 B1 MA32656 B1 MA 32656B1
Authority
MA
Morocco
Prior art keywords
chemical compounds
new chemical
novel compounds
compounds
excessive
Prior art date
Application number
MA33729A
Other languages
Arabic (ar)
English (en)
Inventor
Steffen Steurer
Peter Ettmayer
Andreas Mantoulidis
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32656(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32656B1 publication Critical patent/MA32656B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouveaux composés représentés par la formule (i) dans laquelle les groupes r1 à r3, x1, x2, x3 et l1 ont la signification donnée dans la revendication 1, ces nouveaux composés étant appropriés pour traiter des maladies caractérisées par une prolifération cellulaire excessive ou anormale; et l'utilisation de tels composés dans un tel traitement.
MA33729A 2008-09-29 2011-03-28 Nouveaux composes chimiques MA32656B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08165437 2008-09-29
PCT/EP2009/062551 WO2010034838A2 (fr) 2008-09-29 2009-09-28 Nouveaux composés chimiques

Publications (1)

Publication Number Publication Date
MA32656B1 true MA32656B1 (fr) 2011-09-01

Family

ID=40019293

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33729A MA32656B1 (fr) 2008-09-29 2011-03-28 Nouveaux composes chimiques

Country Status (20)

Country Link
US (1) US8778929B2 (fr)
EP (1) EP2350052B1 (fr)
JP (1) JP5603869B2 (fr)
KR (1) KR20110063574A (fr)
CN (1) CN102227421A (fr)
AR (1) AR073700A1 (fr)
AU (1) AU2009295855A1 (fr)
BR (1) BRPI0920608A2 (fr)
CA (1) CA2738448A1 (fr)
CL (1) CL2011000691A1 (fr)
CO (1) CO6351739A2 (fr)
EA (1) EA201100564A1 (fr)
EC (1) ECSP11010930A (fr)
IL (1) IL211744A0 (fr)
MA (1) MA32656B1 (fr)
MX (1) MX2011003292A (fr)
PE (1) PE20110294A1 (fr)
TW (1) TW201018670A (fr)
UY (1) UY32146A (fr)
WO (1) WO2010034838A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090837A1 (es) * 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
MX2011003292A (es) 2008-09-29 2011-04-21 Boehringer Ingelheim Int Compuestos antiproliferativos.
CA2752265A1 (fr) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Derives pyrimido-[5,4-d]-pyrimidine pour l'inhibition des tyrosine-kinases
JP2011057661A (ja) 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP2552905B1 (fr) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH Inhibiteurs de la kinase B-Raf
WO2011117382A1 (fr) * 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
AU2012335663B2 (en) 2011-11-11 2015-12-24 Array Biopharma Inc. Method of treating a proliferative disease
AR088936A1 (es) 2011-11-23 2014-07-16 Novartis Ag Formulaciones farmaceuticas
CA2769821C (fr) 2012-02-28 2020-08-11 Michael Hatzinikolas Ensemble structurel a liberation automatique
SG11201407152XA (en) 2012-05-15 2014-11-27 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CN104379574B (zh) 2012-05-15 2017-03-01 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
BR112014027584B1 (pt) 2012-05-15 2023-01-24 Novartis Ag Uso de inibidores da atividade de abl1, abl2 e bcr-abl1, e composição farmacêutica
EA201492007A1 (ru) 2012-05-15 2015-03-31 Новартис Аг Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
WO2017069226A1 (fr) * 2015-10-23 2017-04-27 田辺三菱製薬株式会社 Nouveau composé hétérocyclique aromatique contenant de l'azote
CN106316864A (zh) * 2016-08-22 2017-01-11 苏州天马精细化学品股份有限公司 4‑甲基‑3‑三氟甲基苯胺的制备方法
DK3570834T3 (en) 2017-01-11 2022-02-28 Alkermes Inc Bicyclic inhibitors of histone deacetylase
AU2018313094A1 (en) 2017-08-07 2020-02-20 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
CN108707147A (zh) * 2018-06-20 2018-10-26 桑文军 一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用
MA53225A (fr) * 2018-08-14 2021-06-23 Biogen Ma Inc Agents inhibiteurs d'ask1
CA3121202A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composes pyrrole et pyrazole et leurs procedes d'utilisation
WO2022188792A1 (fr) * 2021-03-12 2022-09-15 四川科伦博泰生物医药股份有限公司 Composé hétérocyclique ayant une activité inhibitrice de protéine kinase, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
CN115772121A (zh) * 2021-09-06 2023-03-10 南通诺泰生物医药技术有限公司 2-甲胺基-3-羟甲基吡啶的制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU507066B1 (en) 1977-09-06 1980-01-31 Sumitomo Chemical Company, Limited 2-Substituted-5-Hydroxy-1h-Imidazole 4-Carbozamide Derivatives
JPH03174153A (ja) 1989-09-20 1991-07-29 Fuji Photo Film Co Ltd カラー画像形成方法
PL184490B1 (pl) 1995-02-02 2002-11-29 Smithkline Beecham Plc Nowe pochodne indolu jako antagonista receptora T
WO1997003967A1 (fr) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Composes aromatiques substitues et leur utilisation pharmaceutique
WO2000047194A2 (fr) 1999-02-09 2000-08-17 3-Dimensional Pharmaceuticals, Inc. METHODES DE TRAITEMENT DE MALADIES ET PATHOLOGIES INDUITES PAR C1s, COMPOSES ET COMPOSITIONS PREPARES A CET EFFET
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
CA2437248A1 (fr) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
ES2338539T3 (es) 2001-11-01 2010-05-10 Icagen, Inc. Pirazolamidas para uso en el tratamiento del dolor.
US20040010027A1 (en) 2001-12-17 2004-01-15 Pharmacia & Upjohn Spa Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
EP1567507B1 (fr) 2002-11-27 2006-06-14 Boehringer Ingelheim Pharmaceuticals Inc. Inhibiteurs de cytokines a base de derives de 1, 2, 3- triazole-amides
BRPI0414313A (pt) 2003-09-11 2006-11-07 Kemia Inc inibidores de citocinas
WO2005030705A1 (fr) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibiteurs d'histone deacetylase
WO2005040152A1 (fr) 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Azolecarboxamides substitues par heterocyclylphenyle et heterocyclylpyridile
ES2360292T3 (es) 2003-12-03 2011-06-02 Boehringer Ingelheim Pharmaceuticals Inc. Derivados de 1,2,3-triazol amida como inhibidores de la producción de citoquinas.
ATE432273T1 (de) 2004-03-09 2009-06-15 Boehringer Ingelheim Pharma 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n- arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
US7485657B2 (en) 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
US7531560B2 (en) 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
TW200628159A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
JP2007076376A (ja) 2005-09-09 2007-03-29 Yanmar Co Ltd トラクタ
WO2007056016A2 (fr) 2005-11-02 2007-05-18 Kemia, Inc. Inhibiteurs de cytokine bisamide
WO2007075896A2 (fr) 2005-12-22 2007-07-05 Kemia, Inc. Inhibiteurs de cytokine heterocycliques
US20070155746A1 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
CA2647266A1 (fr) 2006-04-18 2007-10-25 Boehringer Ingelheim International Gmbh Procede de preparation de composes inhibiteurs des cytokines contenant des cycles 4- et 5-imidazolyle et leurs intermediaires
PE20080068A1 (es) 2006-05-15 2008-03-17 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
EP2041138B1 (fr) 2006-07-07 2014-06-25 Bristol-Myers Squibb Company Inhibiteurs de pyrrolotriazine kinase
PE20080553A1 (es) 2006-07-07 2008-05-16 Schering Corp Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
NZ574621A (en) 2006-07-07 2012-03-30 Boehringer Ingelheim Int Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumour agents
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
PE20080906A1 (es) * 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
WO2008089034A2 (fr) 2007-01-11 2008-07-24 Kemia, Inc. Inhibiteurs de cytokine
AU2008221263B2 (en) * 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
JP2010531850A (ja) 2007-07-02 2010-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
PE20090837A1 (es) 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
BRPI0916356B1 (pt) 2008-07-24 2022-08-23 Nerviano Medical Sciences S.R.L 3,4-diaril pirazois como inibidores da proteína quinase
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
MX2011003292A (es) 2008-09-29 2011-04-21 Boehringer Ingelheim Int Compuestos antiproliferativos.
CA2752265A1 (fr) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Derives pyrimido-[5,4-d]-pyrimidine pour l'inhibition des tyrosine-kinases
WO2011117382A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
EP2552905B1 (fr) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH Inhibiteurs de la kinase B-Raf
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
AU2009295855A1 (en) 2010-04-01
MX2011003292A (es) 2011-04-21
AR073700A1 (es) 2010-11-24
EP2350052A2 (fr) 2011-08-03
CA2738448A1 (fr) 2010-04-01
EP2350052B1 (fr) 2014-08-13
UY32146A (es) 2010-04-30
CN102227421A (zh) 2011-10-26
JP5603869B2 (ja) 2014-10-08
US8778929B2 (en) 2014-07-15
PE20110294A1 (es) 2011-05-26
US20110312939A1 (en) 2011-12-22
TW201018670A (en) 2010-05-16
WO2010034838A3 (fr) 2010-11-18
WO2010034838A2 (fr) 2010-04-01
KR20110063574A (ko) 2011-06-10
CO6351739A2 (es) 2011-12-20
EA201100564A1 (ru) 2011-12-30
CL2011000691A1 (es) 2011-07-29
JP2012504114A (ja) 2012-02-16
ECSP11010930A (es) 2011-04-29
IL211744A0 (en) 2011-06-30
BRPI0920608A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
MA32656B1 (fr) Nouveaux composes chimiques
MA32120B1 (fr) Nouveaux composes chimiques
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA33832B1 (fr) Isoquinolinones et quinazolinones substituées
MA32598B1 (fr) Nouveaux benzamides, leur preparation et leur utilisation comme medicaments
MA31710B1 (fr) (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament
MA30912B1 (fr) Nouveaux derives de phenylsulfamoyl-benzamide en tant qu'antagonistes de la bradykinine
MA31419B1 (fr) Derives de pyridine
EP2571876A4 (fr) Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
MA30402B1 (fr) Acides carboxyliques substitues par des phenylamino-benzoxazoles, leur procede de production et leur utilisation comme medicaments
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA27946A1 (fr) Omega-carboxyaryldiphenyluree fluoro-substituee pour le traitement et la prevention de maladies et d'etats pathologiques.
EP1305024A4 (fr) Procede de traitement des maladies fibreuses ou autres indications
MA31076B1 (fr) Dérivés de l'isoquinoléine et de l'isoquinoléinone substitués par une cycloalkylamine.
MA31024B1 (fr) Nouveaux derives de l'isoquinoleine et de l'isoquinoleinone substituees
MA31075B1 (fr) Dérivés d'isoquinolone substitués par une cycloalkylamine.
MA27734A1 (fr) DERIVES HEXAHYDROPYRAZINO [1,2-a]PYRIMIDINE-4,7-DIONE SUBSTITUES SUR L'AZOTE, METHODE POUR LEUR PRODUCTION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS
MA30609B1 (fr) Imidazolidine-2,4-diones arylaminoaryl-alkyl-substituees, leur procede de synthese, les medicaments comprenant ces composes, et leurs applications.
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
MA31570B1 (fr) Oxazolidinones substitués et leur utilisation
TN2009000138A1 (fr) Biaryl-ether-urees
EP2190428A4 (fr) Composés hétérocycliques en tant qu'inhibiteurs de dipeptidylpeptidase-iv pour le traitement ou la prévention des diabètes
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase